Additionally, a Phase 2 trial has demonstrated that the combination of octreotide and the mTOR inhibitor everolimus exhibits clinical activity and reduces tumor growth in WHO grade 1–3 meningiomas. This evidence concerns the gene MTOR and neoplasm.